Article

Kidney Cancer: Know the Risk Factors

In conjunction with Kidney Cancer Awareness Month, learn more about risk factors and treatment options for the disease.

March is recognized as Kidney Cancer Awareness Month — a disease that is among the top 10 most common cancers in both men and women, according to the National Cancer Institute.

Some factors for kidney cancer can include:

  • Occupation hazards
  • Obesity
  • Smoking

In addition, certain factors — such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma (RCC) – a common type of kidney cancer. Specific risk factors related to obesity may increase a person’s chance of developing renal RCC. according to recent research conducted at Spectrum Health. Other causal factors indicated by the American Institute for Cancer Research include certain medications, kidney disease and hypertension.

Fortunately, new drugs are consistently appearing in the treatment landscape for kidney cancer and patients with renal cell carcinoma have more treatment options than ever before, including immunotherapy.

Additionally, meeting combined exercise guidelines — including both aerobics and strength training – improved quality of life in kidney cancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.

To stay up to date on kidney cancer and cancer in general, sign up for CURE’s eNewsletters.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content